Analyzing EGFR mutations and detecting ALK gene fusion are indispensable when planning to treat pulmonary adenocarcinoma. Malignant pleural effusion (MPE) is a devastating complication of lung cancer and sometimes the only source for mutation analysis. The percentage of tumor cells in the pleural effusion may be low; therefore, mutant enrichment is required for a successful analysis. The EGFR mutation status in MPE was determined using three methods: (1) PCR sequencing of genomic DNA (direct sequencing), (2) mutantenriched PCR sequencing of genomic DNA using peptide nucleic acid (PNA-sequencing), and (3) PCR sequencing of cDNA after reverse transcription for cellular RNA (RNAsequencing). RT-PCR was also used to test cases for ALK gene fusion.
Introduction
EGFR mutations are either exon 19 deletion (exon 19 del) or L858R in exon 21. [9] On this base, PNA-sequencing on common mutations was developed to meet clinical needs. [9] A recent cohort study [16] reported using RNA as a favorable source for analyzing EGFR mutations in MPE. It was believed that mutant EGFR mRNA from tumor cells was enriched in the RNA samples from pleural effusions because the non-tumor cells produced little wild-type EGFR mRNA. [16] The aim of this study was to assess the sensitivity of EGFR mutation analysis using direct sequencing, PNA-sequencing, and RNA-sequencing of MPE in lung adenocarcinoma.
Materials and Methods Patients
Effusion with abnormal cytology (malignancy, suspicious, atypical) was centrifuged and the cell pellet was stored for molecular testing. From January 2011 to June 2015, there were 160 molecular tests for pleural effusion ordered at our hospital. Their cytology diagnoses included: 157 "malignancy", 2 "suspicious for malignancy", and 1 "atypical cells". Eighty-five of the 157 malignant cases had subtyping information in the diagnoses: 71 adenocarcinoma and 14 NSCLC not otherwise specified (NSCLC-NOS). Forty-one cases had biopsy tissue proof, all of which were adenocarcinoma. One hundred forty-two cases had enough cells for both DNA and RNA tests, 16 for RNA tests only, and 2 for DNA tests only. The 142 cases were used for methodological comparison. Seventy-three of the 142 malignant cases had subtyping information in the diagnoses, including 62 adenocarcinoma and 11 NSCLC-NOS. The RNA test covers exons 18-21 of EGFR; the PNA tests for exon 19 del and L858R in exon 21 have good performance and cover approximately 90% of all EGFR mutations. Other mutations are much less cost-effective if PNA were used. Because our PNA test was not designed to detect mutations in exons 18 and 20, we excluded 9 such cases. All 9 patients were diagnosed by RNA-sequencing, including five exon 18 mutations (1 G709A, 3 G719A, and 1 G719S) and 4 exon 20 mutations (2 p.Ala767_Val769 dup, 1 p.Ser768_Asp770 dup, and 1 p.Val769_Asp770 ins CG). The remaining 133 cases contained either wild-type EGFR or the common mutations (exon 19 del or L858R).
This study was approved by National Cheng Kung University Hospital's Institutional Review Board (IRB #: B-BR-101-137). All patients signed a written informed consent form for molecular analysis.
Demographic and clinical information of these patients was recorded: age, sex, smoking history, tumor staging, performance status (Eastern Cooperative Oncology Group performance status (ECOG PS), [30] treatment regimens, and maximal response. Patients who had smoked fewer than 100 cigarettes in their lifetime were categorized as never smokers, and those who had smoked more than 100 cigarettes were categorized as former smokers. The response to gefitinib was evaluated in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. [31] [32] [33] Specimen collection and preparation Pleural effusion was collected in sterile tubes. Samples (15 mL) were centrifuged at 250 × g for 10 min, and the cell pellet was stored in a reagent (RNAlater; Qiagen, Hilden, Germany) at −80°C until use. If the cellularity was high enough, samples were also submitted for DNA extraction. Both RNA and DNA for molecular analysis were extracted in approximately 89% (142/160) of the MPEs.
Extracting genomic DNA and RNA from cell pellets One kit (QIAmp DNA Mini Kit; Qiagen) was used to extract genomic DNA from cell pellets, and another (RNeasy; Qiagen) to extract RNA from stored cell pellets.
PCR sequencing of cDNA from cell-derived RNA (RNA-sequencing)
The reverse transcriptase (RT)-PCR was done using reverse transcriptase (Superscript II; Invitrogen, Carlsbad, CA) as previously described. [34] Exons 18-21 of the EGFR were amplified using specific primer sets ( Table 1 ). The amplicons (557 bp) were purified and sequenced using a kit (BigDye Terminator Sequencing Kit; Applied Biosystems, Foster City, CA). The sequencing products underwent electrophoresis using ABI 3500 genetic analyzer (ABI Prism 3500; Applied Biosystems). The sequences were compared with the EGFR sequences in the GeneBank from the National Center for Biotechnology Information (NCBI) (accession number NM_005228.3). Both forward and reverse sequences were analyzed, and the original chromatograms were manually examined by two medical technologists.
Direct sequencing and PNA-sequencing using cell-derived genomic DNA Exons 18, 19, 20 , and 21 of the EGFR gene were amplified using culture-independent nested PCR (Table 1) as previously described. [17, 21, 35] For PNA-sequencing, PNA is used to construct the PCR clamp reactions; the PNA clamp suppresses the amplification of wild-type DNA, thereby increasing the preferential amplification of the mutant sequences. PNA oligos were synthesized by Bio-Synthesis, Inc. (Lewisville, TX). The mutant-enriched PCR was done in a mixture of PCR primers (10 μM each), PNA oligo (100 μM each), genomic DNA (25 ng), Table 1 . PCR primers and the PNA sequences. and a DNA polymerase (Super Therm Gold Master Mix; Bionovas Biotechnology, Toronto, Ontario, Canada). The PCR amplicons were purified and then subjected to bidirectional sequencing.
PCR amplification
The PCR was done using a thermal cycler (G-Storm; GMI, Inc., Ramsey, MN). The cycling was as follows: 95°C for 6 min, 35 cycles of 95°C for 30 s, 60°C for 1 min, and 72°C for 1 min. Nested PCR for EGFR mutation analysis was done using the same reaction conditions.
Constructing plasmid clones of EGFR exons 19 and 21 sequences and of mixed cell lines
The pGEMT easy vector plasmids, which contain EGFR exon 19 del (E746_A750 del) or L858R mutations, were derived from human primary NSCLC tissue using PCR cloning. The sequence of each plasmid was confirmed using Sanger sequencing. To evaluate the sensitivity of PNA-sequencing, plasmid DNAs containing EGFR mutants were serially diluted with genomic DNA from A549 cells with wild-type EGFR. To determine the detection limit of EGFR mutations at the cellular level, genomic DNA with E746_A750 del was extracted from H1650 cells and mixed with genomic DNA from A549 cells (wild-type EGFR) in ratios ranging from 1:1 to 1:100. The A549 and H1650 cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). Similarly, to determine the detection limit of EGFR mutations at the RNA level, total RNA from H1650 and A549 cells was mixed in ratios ranging from 1:1 to 1:100.
RT-PCR quality control
For quality control, two primer pairs were used to amplify the GAPDH (165 bp) and β2-microglobulin (256 bp) genes from 25 ng of each sample. [36] Primers for GAPDH were: GAA GGT GAA GGT CGG AGT C and TGG AAT TTG CCA TGG GTG GA; primers for β2-microglobulin were: TGG AGG CTA TCC AGC GTA CT and CGG CAG GCA TAC TCA TCT TT. The final concentrations of the primers were 0.8 μM in a 25-μL reaction. PCR conditions were as follows: 95°C for 30 s, followed by 35 cycles each of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s with a final 10-min extension at 72°C. Gel electrophoresis was done using a 2% agarose gel.
Detecting the EML4-ALK fusion gene using multiplex PCR
The procedure for EML4-ALK multiplex PCR was adapted from Sanders et al. [14] and Soda et al., [11] using Super Therm Gold Master Mix (Bionovas) in one tube. The primers used are shown in Table 2 . The most common fusion types of KIF5B-ALK were detected using the primers in Table 2 . Reaction conditions were: one cycle of 95°C for 5 min, followed by 35 cycles of 95°C for 30 s, 60°C for 30 s, 72°C for 30 s, and then one cycle of 72°C for 10 min. RT-PCR amplicons were purified and sequenced using a kit (Big Dye Terminator Sequencing Kit; Applied Biosystems). The different variants were determined and then compared with previously published reports.
Statistical analysis
Patient characteristics (sex, tumor histology, and smoking habit) were tabulated in relation to the mutation status. Fisher's exact test was used to analyze associations between patient characteristics and the presence of EGFR mutations. Significance was set at p < 0.05 (two-sided). SPSS 17.0 for Windows (SPSS Inc., Chicago, IL) was used for all analyses.
Evaluating the response to EGFR-TKI
The tumor response to EGFR TKI was evaluated using chest X-rays of the disease sites every 2-4 weeks, and computed tomography [30] every 8-12 weeks after treatment. Treatment responses were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) using the unidimensional method. [37, 38] Results
Sensitivity assays using cloned EGFR DNA fragments
To determine the sensitivity of PNA-sequencing, cloned DNA fragments (mutants) were serially diluted in genomic DNA from A549 cells (wild-type EGFR) with various calculated gene copy numbers. The analytical sensitivity of PNA-sequencing was estimated to be less than (better than) 1% for both E746_A750 del ( Fig 1A) and L858R mutations (Fig 1B) . Consistent with general experiences with frame-shift mutations, PCR direct sequencing showed a sensitivity of 10% for E746_A750 del (Fig 1A) .
Sensitivity assays using cell lines with EGFR mutations
We used mixed cell lines to estimate the sensitivities at the cellular level. Genomic DNA from H1650 cells (E746_A750 del) and A549 cells (wild-type EGFR) was mixed in ratios ranging from 1:1 to 1:100. Consistent with the above assay using cloned DNA fragments, the analytical sensitivity of PNA-sequencing for E746_A750 del was estimated to be < 1% at the cellular level (Fig 1C) . For RNA-sequencing, complementary DNA was obtained using RT-PCR sequencing. The sensitivity of RNA-sequencing was similar to that of the PNA-sequencing at the cellular level (< 1%) (Fig 1C) .
Detecting EGFR mutations using direct-, PNA-and RNA-sequencing
The analytical sensitivities of PNA-sequencing and RNA-sequencing met our criterion for EGFR mutation analysis (< 1%). They were subsequently used for routine clinical testing. PCR direct sequencing was also used as a companion test to PNA-sequencing. If a mutation was detected using any one of the 3 methods, a positive report was issued. From January 2011 to June 2015, there were 160 molecular tests done for pleural effusion; 101 were positive for EGFR mutations (63%). One hundred forty-two of the 160 cases had enough cells for both DNA and RNA tests. The mean age of the patients was 69.0 years (range: 31-100 years). EGFR mutation was detected in 96 cases (67.6%). EGFR mutations were not associated with sex (men: 30.9% versus women: 36.6%; p = 0.275) and smoking history (37.3% of never smokers versus 7.0% of former or current smokers; p = 0.321), but associated with age 65 (p = 0.008). (S1 Table) . Sensitivity assays using cloned DNA fragments or cell lines. Cloned DNA fragments containing the (A) EGFR E746_A750 del or (B) EGFR L858R mutation were serially diluted in genomic DNA from A549 cells with wild-type EGFR. Direct sequencing of PCR products (direct sequencing; left column) and mutant-enriched PCR sequencing using peptide nucleic acid (PNA-sequencing; right column) were done to determine their analytical sensitivities. The arrows indicate the detected mutation sites. (C) Genomic DNA or total RNA from H1650 cells (E746_A750 del) and A549 cells (wild-type EGFR) were mixed in ratios ranging from 1:1 to 1:100. The DNA underwent direct sequencing and PNA-sequencing. The RNA was underwent PCR sequencing of cDNA after reverse transcription (RNA-sequencing). The arrows indicate the detected mutation sites. The sequencing chromatograms from the lowest detectable ratios are shown in the panel. 
Discrepancy using different detection methods
Parallel analysis showed that RNA-sequencing and PNA-sequencing were significantly (p < 0.0001) correlated (Table 4) .
Clinical response to EGFR-TKIs
Forty-seven of the 87 patients with EGFR mutations (exon 19 deletions or L858R) received TKIs treatment in our hospital. The clinical decisions were all based on EGFR mutations detected in MPE. The best clinical responses according to RECIST after TKIs treatment were: 15 partial response (32%), 22 stable disease (47%), and 10 progressive disease (21%). Fig 2 shows one patient as an example. The MPE was tested negative by DNA-sequencing (Fig 2A) , but RNA and PNA-sequencing showed exon 19 E746_A750 del (Fig 2B and 2C) . The tumor shrank from 2.1 to 1.7 cm (19%) after 18 months of TKI treatment (Fig 2D and 2E) . Multiplex RT-PCR for detecting ALK gene fusion Multiplex RT-PCR, which was then used to test all 113 cases for EML4-ALK and KIF5B-ALK gene fusion, detected that five of 46 (10.8%) wild-type EGFR cases had EML4-ALK fusion. All of them were variant 1 (E13; A20), which was confirmed using Sanger sequencing (Fig 3) . The 67 cases with exon 19 del or L858R mutations showed negative results.
Clinical response to ALK-TKIs
Two of the 5 patients with ALK fusions received Ceritinib treatment in our hospital. The clinical decisions were based on ALK Fluorescent in Situ Hybridization performed on tissue biopsy following the detection of ALK fusion in MPE. The best clinical responses according to RECIST after TKIs treatment were: 1 partial response and 1 progressive disease. Fig 3 shows the EML4-ALK fusion gene sequencing and the CT images of the patient with partial response. The tumor shrank from 2.4 to 1.5 cm (36%) after 6 months of TKI treatment (Fig 3B and 3C ).
Discussion
The traditional method for EGFR mutation analysis is direct-sequencing, a technique in which non-malignant cells are likely to interfere with in a heterogeneous tissue sample. [24, 39] Tsai et al. [16] reported that RNA-sequencing was significantly more sensitive for detecting EGFR mutations (67.3% vs. 44.7%). Consistent with other studies, [16] in 133 cases, we detected only 75 (56.4%) exon 19 del and L858R mutations using direct-sequencing compared with 87 (65.4%) using RNA-sequencing. Such a result is compatible with the notion that RNAsequencing is more sensitive than direct-sequencing (using DNA) because of the natural enrichment of the mutant EGFR mRNA in the cells of pleural effusion. We found that RNA-sequencing was slightly more sensitive than PNA-sequencing in clinical samples (65.4% vs. 63.2%, respectively). This is because the sensitivity of RNA-sequencing is determined by the total EGFR expression level, not by the number of background cells (mesothelial and inflammatory cells). In contrast, the sensitivity of DNA-based PNA-sequencing depends solely upon the number of background cells. The tumor cells have the mutant genome and they express the mutant EGFR mRNA. The background cells within MPEs have considerably lower EGFR expression in comparison with the overexpression of EGFR in NSCLC cells. Because PNA does not completely (100%) block the wild-type background signal, all of the genomic DNA of the background cells will contribute to wild-type signals in PNAsequencing. However, if the background cells express a very low level of EGFR, the mutant EGFR expressed by the tumor cells will be highly enriched in RNA-sequencing, no matter how many background cells there are. Using H1650 as a background, PNA-sequencing and RNAsequencing had similar sensitivities (Fig 1) . It is possible that the background cells in MPE have even lower EGFR expression than do H1650 cells, which makes the RNA-sequencing more sensitive than PNA-sequencing in clinical samples.
We found that RNA-sequencing might reveal discrepancies between gene mutations in genomic DNA and in mRNA. PNA-sequencing found double mutations (E745_A750 del and L858R) in one case in this study, which RNA-sequencing showed as only singly mutated at L858R. Whether two common sensitive mutations (E745_A750 del and L858R) can reside in the same EGFR molecule is an interesting question.
The sensitivities of EGFR mutation detection were 56.4% for direct-sequencing, 63.2% for PNA-sequencing, and 65.4% for RNA-sequencing. The detection rates in our study were higher than those in Hung et al., [20] who reported a 41% (12/29) detection rate using direct-sequencing, but comparable to those in Tsai et al., [16] who reported a 67.3% detection rate using RNA-sequencing. Altogether, EGFR mutation in the MPE of lung adenocarcinoma is generally between 60% and 70% in Taiwan, regardless of the patient's sex, smoking status, and age. Additional prospective studies are needed to confirm our observation.
Among When clinically detecting EGFR mutations, several things need to be considered. For PNA-sequencing, the only modification is to add PNA to the PCR mixture. No additional cost for instruments is required. The technology is simple, rapid, and cost-effective for detecting specific mutant DNA sequences. For RNA-sequencing, careful handling to avoid ribonuclease (RNase) activity is critical for successful testing. Commercially available RNA stabilizing reagents together with refrigeration can minimize RNA degradation. Actually, fusion gene testing based on RT-PCR is a routine procedure for leukemia in many molecular laboratories and should not prohibit using RNA to test the cellular component of pleural effusions. However, the workflow of sample collection and transport should be streamlined to avoid RNA degradation. RNA is an ideal material for detecting fusion genes, not only for ALK, but also for ROS1 and RET found in lung adenocarcinoma. [40] The subtypes of gene fusions can be identified using RT-PCR and Sanger sequencing. It is conceivable that different subtypes respond differently to different TKIs. Such additional benefits may justify the workflow changes for RNA testing. The most sensitive method for EGFR and ALK testing might be true only when the testing specimen is pleural effusion. Generally, RNA-based techniques are not practical for general diagnosis, especially in reference laboratories that receive samples from many centers.
EGFR mutations and ALK gene fusion were thought to be mutually exclusive events in lung adenocarcinoma. Our finding that ALK gene-fusion-positive cases are all negative for EGFR mutations might support this notion. However, evidence that the co-occurrence of the two driver mutations is not uncommon, and that such cases might benefit from dual treatments with both EGFR and ALK TKIs, has recently been reported. [41] When treated with a single TKI, ALK TKI might be a better choice than EGFR TKI. [41] It is highly likely that in the near future, comprehensive molecular diagnoses for lung adenocarcinoma will include both EGFR and ALK testing. EGFR mutation analysis alone may not be adequate, because a patient with a sensitive EGFR mutation might have a concomitant ALK fusion, which might require ALK TKI for optimal treatment.
In conclusion, we have provided evidence that supports MPE as a practical specimen for molecular analysis in patients with NSCLC. RNA-sequencing is more sensitive than PNAsequencing for detecting EGFR mutations for targeted therapy. PNA-sequencing can be used as an alternative when RNA quality is not optimal. We suggest RNA-sequencing for EGFR mutations and RT-PCR for ALK gene fusion for comprehensive molecular testing of NSCLC MPE.
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